In MM, several members of the signaling lymphocytic activation molecule (SLAM) family have been discovered as high-potential therapy targets including SLAMF7 and SLAMF3, which were uniformly expressed on chemotherapy-resistant MM cells, and CAR-T cells targeting either antigen were highly effective in preclinical experiments (30, 31, 42–44). The gene discussed is SLAMF7; the disease is Miyoshi myopathy.